The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 206-page report you will receive 66 tables and 59 figures– all unavailable elsewhere.
The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Biomarkers Market Research from 2017-2027
• This report also breaks down the revenue forecast for the global biomarkers market by Sector:
– Biomarker Services
– Biomarker Diagnostics
– Biomarker Discovery
• This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
– Genomics
– Proteomics
– Bioinformatics
– Other
• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
– Cancer
– Cardiovascular Diseases
– CNS,
– Autoimmune Diseases
– Other
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– EU5 (further segmented into France, Germany, the UK, Spain and Italy)
– Japan
– China
– India
– Russia
– Brazil
– RoW
• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
– Quintiles IMS Holdings Inc
– Laboratory Corporation of America Holdings
– Parexel
– Charles River Laboratories
– ICON plc
– WuXi PharmaTec
– Caprion Proteomics
– Proteome Sciences
– Pacific Biomarkers
– Oxford Gene Technology (OGT)
– Worldwide Clinical Trials (WWC)
– Agilent
– AB SCIEX
– QIAGEN
– Axela Inc
– Thermo Fisher Scientific
– Quest Diagnostics
– Myriad Genetics
– Genomic Health
– Critical Diagnostics
– Epigenomics
– MDxHealth (formerly OncoMethylome)
• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
– Pfizer
– Novartis
– Roche Diagnostics
– Ventana Medical Systems
– Merck & Co.
– Sanofi
– GSK
– Abbott Laboratories
– AstraZeneca
Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.
Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Biomarkers: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Market Definition, 2016
2. An Introduction to Biomarkers
2.1 Definition of a Biomarker
2.1.1 A Brief History of Biomarkers
2.1.2 The Importance of Biomarkers
2.2 Biomarker Discovery and Validation
2.3 Uses of Biomarkers
2.3.1 Assessing Drug Efficacy
2.3.2 Assessing Drug Safety
2.3.3 Companion Diagnostics
2.3.3.1 CLIA vs. FDA Approval
2.3.4 Therapeutic Importance of Biomarkers
2.3.5 Imaging Biomarkers
2.3.5.1 Imaging Biomarkers in Clinical Trials
2.4 Biomarkers and Personalised Medicine
2.5 Biomarker Discovery
2.5.1 Genomics
2.5.1.1 Pharmacogenomics
2.5.2 Proteomics
2.5.3 Metabolomics
3. The World Biomarkers Market, 2016-2027
3.1 The World Biomarkers Market, 2016
3.1.1 The World Biomarkers Market by Sector, 2016
3.1.2 The World Biomarkers Market by Discipline, 2016
3.2 The World Biomarkers Market: Overall Revenue Forecast, 2016-2027
3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market
3.3 The World Biomarker Discovery Submarket, 2016
3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2016-2027
3.4 The World Biomarker Diagnostics Submarket, 2016
3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2017-2027
3.5 The World Biomarker Services Submarket, 2016
3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2016-2027
3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2016-2027
3.6.1 The Genomics Submarket: Revenue Forecast, 2016-2027
3.6.1.1 Next Generation Sequencing to Drive Growth
3.6.1.2 Increased Focus on Genomic Research in China
3.6.1.3 Application in Cardiovascular Disease
3.6.2 The Proteomics Submarket: Revenue Forecast, 2016-2027
3.6.2.1 Advances in Detection Technology Will Drive Market
3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2016-2027
3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline
3.7 Growth in Key Biomarker Disciplines, 2016-2027
4. Leading Indications for Biomarker Discovery and Development, 2016-2027
4.1 The World Biomarkers Market by Indication, 2016
4.1.1 Class of biomarkers
4.1.2 Pharmacodynamic Biomarkers
4.2 The World Biomarkers Market: Overall Revenue Forecast by
Indication, 2016-2027
4.3 Cancer Biomarker Market
4.3.1 A Brief History of Cancer Biomarker Research
4.3.2 The Current State of Cancer Biomarker Research
4.3.3 Companion Diagnostics for Cancer
4.3.4 Initiatives in Cancer Biomarker Research
4.3.4.1 Cancer Genome Atlas
4.3.4.2 The Early Detection Research Network
4.3.5 Many Cancer Diagnostics Are Reaching the Market
4.3.6 Opportunities and Challenges for Cancer Biomarkers
4.3.6.1 Prostate Cancer: The Search for Urine Biomarkers
4.3.6.2 Lung Cancer: High Biomarker Owing to Disease Prevalence
4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2016-2027
4.4 Cardiovascular Disease Biomarker Submarket 2016
4.4.1 A Brief History of Cardiovascular Biomarker Research
4.4.2 The Current State of Cardiovascular Disease Biomarker Research
4.4.3 Cardiovascular Disease Diagnostics
4.4.3.1 Roche Troponin Test Approved by FDA
4.4.4 Collaborations in Cardiac Biomarker Research
4.4.4.1 Bayer Health Extends Collaboration with Broad Institute and Harvard
4.4.4.2 Singulex Inc Collaboration with University of Manchester
4.4.5 The Future of Cardiovascular Biomarker Research
4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2016-2027
4.5 CNS Diseases Biomarker Submarket, 2016
4.5.1 The Current State of CNS Disease Biomarker Research
4.5.2 Initiatives in CNS Disease Biomarker Research
4.5.3 Biomarker-Based Diagnostics for CNS Diseases
4.5.3.1 ADtect (DiaGenic)
4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare)
4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly)
4.5.3.4 Flutemetamol (GE Healthcare)
4.5.3.5 Florbetaben (Piramal Imaging)
4.5.4 CSF Biomarkers
4.5.5 Alzheimer’s Disease: Beyond Amyloid Beta
4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
4.5.6 Multiple Sclerosis: Search for Disease Biomarker
4.5.7 Parkinson’s Disease: Effective Biomarker Yet to be Discovered
4.5.7.1 Fluid-Based Biomarker Discovery
4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
4.6 Autoimmune Disease Biomarker Submarket, 2016
4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease
4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease
4.6.2.1 Ventra DA – Myraid Genetics
4.6.2.2 NavigAID SSc – Protagen AG
4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer
4.6.3 Increasing consolidation within the market
4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders
4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics
4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
4.7 Growth in Key Biomarker Indications, 2016-2027
5. Leading National Biomarker Markets, 2017-2027
5.1 The World Biomarkers Market: Regional Breakdown, 2016
5.2 The World Biomarkers Market: Regional Forecast, 2016-2027
5.3 US Biomarkers Market, 2016
5.3.1 FDA – New Draft Guidance on Companion Diagnostics
5.3.2 FDA major shift in regulation of laboratory developed tests
5.3.3 The US Biomarker Market: Revenue Forecast, 2016-2027
5.4 EU5 Biomarker Markets, 2016
5.4.1 EMA – New Draft Guidance on Companion Diagnostics
5.4.2 EMA – New Draft Guidance on Alzheimer’s Treatment
5.4.3 EU5 Biomarker Markets: Revenue Forecasts, 2016-2027
5.4.4 Germany Biomarker Market, 2016
5.4.4.1 Government initiatives: CancerMark Project
5.4.4.2 Germany: Biomarker Market Revenue Forecast, 2017-2027
5.4.5 France Biomarker Market, 2016
5.4.5.1 French Government Funds $17m Cancer Biomarker Effort
5.4.5.2 Immunid Received Funding for Companion Diagnostic for Skin Cancer
5.4.5.3 France: Biomarker Market Revenue Forecast, 2016-2027
5.4.6 UK Biomarker Market, 2016
5.4.6.1 Current stage of biomarker research in the UK
5.4.6.2 100,000 Genomes Project
5.4.6.3 £10 Million investment in Precision Panc project
5.4.6.4 The UK Biomarker Market: Revenue Forecast, 2017-2027
5.4.7 Spain Biomarker Market, 2016
5.4.7.1 Spain: Biomarker Market Revenue Forecast, 2016-2027
5.4.8 Italy Biomarker Market, 2016
5.4.8.1 Italian Government Initiatives on Genomics
5.4.8.2 Italy: Biomarker Market Revenue Forecast, 2017-2027
5.5 Japan Biomarker Market, 2016
5.5.1 PMDA – Guidance on Companion Diagnostics
5.5.2 Japan: Biomarker Market Revenue Forecast, 2017-2027
5.6 China Biomarker Market, 2016
5.6.1 Expanding Economy Driving Biotechnology in China
5.6.2 Companies Entering the Chinese Market
5.6.3 China: Biomarker Market Revenue Forecast, 2017-2027
5.7 India Biomarker Market, 2016
5.7.1 GenomeAsia 100K
5.7.2 New cancer institute funded by Indian Government
5.7.3 India: Biomarker Market Revenue Forecast, 2017-2027
5.8 Russia Biomarker Market, 2016
5.8.1 Russia: Biomarker Market Revenue Forecast, 2017-2027
5.9 Brazil Biomarker Market, 2016
5.9.1 Brazil: Biomarker Market Revenue Forecast, 2017-2027
5.10 RoW Biomarker Market, 2016
6. Biomarker Industry Trends, 2017-2027
6.1 Strengths and Weaknesses of the Biomarkers Market, 2016
6.2 Opportunities and Threats in the Biomarkers Market, 2017-2027
6.3 STEP Analysis of The World Biomarkers Market
6.4 Social Factors
6.4.1 Patient Stratification: Striving Towards Personalised Medicine
6.4.2 Biomarker Hype May Not Always Lead to New Discoveries
6.4.3 Growing Emphasis on Oncology for Companies
6.5 Technological Factors
6.5.1 Decreasing Size, Increasing Sensitivity
6.5.1.1 ABT Molecular Imaging
6.5.2 The Need for More-Efficient Data Storage
6.6 Economic Factors
6.6.1 Biomarkers: Cutting the Cost of Drug Development
6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures
6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups
6.6.3 Outsourcing Biomarker Discovery and Development
6.7 Political Factors
6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery
6.7.2 Improving Regulatory Guidelines to Speed Development
6.7.3 Concerns Over Biomarker Patenting Hits Innovation
6.8 Challenges in Developing Biomarkers
6.9 Combining Drug and Diagnostic Development
6.10 MicroRNA Biomarkers: A Prospective Target?
6.11 Big Pharma and Biomarkers
6.11.1 Pfizer
6.11.2 Novartis
6.11.3 Merck & Co.
6.11.4 Sanofi
6.11.5 Roche
6.11.5.1 Roche Diagnostics
6.11.5.2 Ventana Medical Systems
6.11.6 GSK
6.11.7 AstraZeneca
6.11.8 Abbott Laboratories
7. Leading Companies in the Biomarkers Market, 2016
7.1 Biomarker Service Providers
7.1.1 Global CROs and Biomarkers
7.1.1.1 Not All Global CROs Are Investing in Biomarkers
7.1.2 Quintiles IMS Holdings Inc
7.1.2.1 Quintiles and IMS Health Merger
7.1.3 Laboratory Corporation of America Holdings
7.1.3.1 LabCorp Diagnostics
7.1.3.2 Covance Drug development
7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2016
7.1.4 Parexel
7.1.5 Charles River Laboratories
7.1.6 ICON plc
7.1.7 WuXi PharmaTec
7.1.8 Caprion Proteomics
7.1.9 Proteome Sciences
7.1.10 Pacific Biomarkers
7.1.11 Oxford Gene Technology
7.1.12 Worldwide Clinical Trials
7.2 Biomarker Technology Providers
7.2.1 Agilent
7.2.1.1 Diagnostics and Biomarker Assays
7.2.1.2 Growing Asian Markets: Focus on South Korea
7.2.2 AB SCIEX
7.2.2.1 Partnership with Illumina, OneOmics project
7.2.3 QIAGEN
7.2.4 Axela
7.2.5 Thermo Fisher Scientific
7.2.5.1 Strategic Acquisitions
7.2.5.2 Research Collaborations
7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre
7.3 Biomarker Diagnostic Developers
7.3.1 Quest Diagnostics
7.3.1.1 Acquisition of Med Fusion and ClearPoint Diagnostics
7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc
7.3.2 Myriad Genetics
7.3.2.1 Pipeline
7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic
7.3.2.3 Strategic Acquisitions
7.3.2.4 Myriad RBM
7.3.3 Genomic Health
7.3.3.1 Collaborations with Epic Sciences and Biocartis
7.3.4 Critical Diagnostics
7.3.5 Epigenomics
7.3.5.1 Diagnostic Product Portfolio
7.3.6 MDxHealth
7.3.6.1 Diagnostic Product Portfolio and Pipeline
8. Conclusions
8.1 State of the World Biomarkers Market in 2016
8.2 Growth in the World Biomarkers Market, 2017-2027
8.2.1 Dominance of Leading Western Markets
8.3 The Use of Biomarkers in Drug Discovery and Development
8.4 Demand for New Diagnostics
Appendices
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Figures
Figure 2.1 Definitions of a Biomarker, 2016
Figure 2.2 The Biomarker Discovery and Validation Process, 2016
Figure 3.1 World Biomarkers Market: Market Shares (%) by Sector, 2016
Figure 3.2 World Biomarkers Market: Market Shares (%) by Discipline, 2016
Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2016-2027
Figure 3.4 World Biomarkers Market: Overall Market Forecast ($bn), 2016-2027
Figure 3.5 World Biomarkers Market: Market Shares (%) by Sector, 2021
Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2027
Figure 3.7 Biomarker Discovery Submarket: Drivers and Restraints, 2017-2027
Figure 3.8 Biomarker Discovery Submarket: Revenue Forecast ($bn), 2016-2027
Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast ($bn), 2017-2027
Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2017-2027
Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2016-2027
Figure 3.12 Biomarker Services Submarket: Revenue Forecast ($bn), 2016-2027
Figure 3.13 Genomics Submarket: Revenue Forecast ($bn), 2016-2027
Figure 3.14 Genomics Submarket: Drivers and Restraints, 2016-2027
Figure 3.15 Proteomics Submarket: Drivers and Restraints, 2017-2027
Figure 3.16 Proteomics Submarket: Revenue Forecast ($bn), 2016-2027
Figure 3.17 Bioinformatics Submarket: Revenue Forecast ($bn), 2016-2027
Figure 3.18 Bioinformatics Submarket: Drivers and Restraints, 2016-2027
Figure 3.19 World Biomarkers Market: Market Shares (%) by Discipline, 2021
Figure 3.20 World Biomarkers Market: Market Shares (%) by Discipline, 2027
Figure 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
Figure 4.2 Pharmacodynamic Biomarkers in Drug Labelling by Indication
Figure 4.3 Cancer Submarket: Revenue Forecast ($bn), 2016-2027
Figure 4.4 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2016-2027
Figure 4.5 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
Figure 4.6 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
Figure 4.7 World Biomarkers Market: Market Share (%) by Indication, 2021
Figure 4.8 World Biomarkers Market: Market Shares (%) by Indication, 2027
Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2016
Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2021
Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2027
Figure 5.4 US Biomarkers Market: Revenue Forecast ($bn), 2017-2027
Figure 5.5 Top 5 EU Biomarker Markets: Market Share (%) by Country, 2016
Figure 5.6 Top Five EU Biomarker Markets: Revenue Forecasts ($bn), 2017-2027
Figure 5.7 Germany: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.8 France: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.9 UK Biomarker Market: Revenue Forecast ($bn), 2017-2027
Figure 5.10 Spain: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.11 Italy: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.12 Japan Biomarker Market: Revenue Forecast ($bn), 2017-2027
Figure 5.13 China: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.14 India: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.15 Russia: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.16 Brazil: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 5.17 RoW: Biomarker Market Revenue Forecast ($bn), 2017-2027
Figure 6.1 US Cancer Deaths by Tumour Type, 2016
Figure 6.2 Average Cost of Sequencing the Human Genome ($mn), 2005-2015
Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2015-2016
Figure 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2016
Figure 7.4 Genomic Health: Product Revenue ($mn), 2015-2016
Figure 7.5 Epigenomics Revenue ($mn), 2016-2017
Figure 7.6 MDxHealth: Revenue by Source ($mn), 2015-2016
Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2016, 2021 and 2027
Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027
Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease, 2016, 2021 and 2027
Figure 8.4 World Biomarkers Market: Revenues ($bn) by Country, 2016, 2021 and 2027
List of Tables
Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2016
Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016
Table 2.3 Technologies and Platforms for Biomarker Research, 2016
Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2016
Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2016
Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2016-2027
Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2016, 2021, 2027
Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2016-2027
Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2016
Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2016, 2021, 2027
Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2016-2027
Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2016
Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2016
Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 4.7 Research Collaborations in CNS Biomarker Research
Table 4.8 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 4.9 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
Table 4.10 World Biomarkers Market: Market Share (%) by Indication, 2016, 2021, 2027
Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2016
Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2016, 2021, 2027
Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2016
Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
Table 5.7 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.8 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 5.17 RoW: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2017-2027
Table 6.2 World Biomarkers Market: Opportunities and Threats, 2017-2027
Table 6.3 World Biomarkers Market: STEP Analysis, 2017-2027
Table 6.4 US Cancer Deaths by Tumour Type, 2016
Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2016
Table 6.6 PSTC Biomarkers in Development, 2016
Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015
Table 6.8 IMI-Funded Biomarker Projects
Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2016, 2021 & 2027
Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2015-2016
Table 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2016
Table 7.4 Company Revenue by Sector ($mn), 2016
Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2016
Table 7.6 Genomic Health: Revenue by Division ($bn), 2015-2016
Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2015 -2016
Table 7.8 MDx Health: Revenue by Source ($mn), 2015-2016
Table 7.9 MDxHealth: Pipeline, 2016
Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2016, 2021 and 2027
Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2016, 2021 and 2027
Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2016, 20121 and 2027
Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2016, 2021 and 2027
